-
Mashup Score: 5Long PrEP – захищає від інфікування ВІЛ статевим шляхом - 1 month(s) ago
Long PrEP — це нова форма PrEP, яка має тривалу дію і передбачає внутрішньом’язові ін’єкції, які вводяться за схемою: 2 ін’єкції вводяться з інтервалом у 4 тижні, наступні — кожні 8 тижнів. В Україні Long PrEP доступний у рамках пілотної програми для людей, які мають підвищений ризик інфікування ВІЛ. У 2023-2024 році передбачена участь 100 клієнтів, які зможуть першими отримати новітню форму доконтактної профілактики ВІЛ-інфекції. Крок 1. Розберемось із назвою. Всі ці назви, які ти міг бачити в соцмережах
Source: long.prep.com.uaCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0
For this to be a viable HIV reduction strategy, scale-up demand creation should be coordinated between all partners, the study authors said, and should be fast enough to build momentum and yield the expected results.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
For this to be a viable #HIV reduction strategy, scale-up demand creation should be coordinated between all partners, the study authors said, and should be fast enough to build momentum and yield the expected results. #cabotegravir https://t.co/hAzolpPQzg
-
-
Mashup Score: 0
Dr Fareed Abdullah said CAB-LA has been proven as the most effective HIV prevention available to Southern Africa because it is ministered every 8 weeks as opposed to the intake of one pill every day.
Source: 702Categories: HIV/AIDS, Latest HeadlinesTweet-
🎧 Listen to a new interview in which @iamfreetsm talks to @fareedabdullah0 (@MRCza) about the significance and potential impact of #Zimbabwe 🇿🇼 approving #cabotegravir, a long-acting injectable form of PrEP. https://t.co/qwPOBIDm0w
-
-
Mashup Score: 1FDA Expands Label of Cabotegravir and Rilpivirine Dual Injectable for Adults With HIV - 2 year(s) ago
The FDA label expansion means adults living with HIV can now receive an injection of cabotegravir and rilpivirine (Cabenuva) once every 2 months instead of once monthly.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#ICYMI: The FDA expanded their approval of dually administered bimonthly #cabotegravir and #rilpivirine, the first and only long-acting regimen to treat #HIV infection in adults. https://t.co/5VpIpsaRt8
-
-
Mashup Score: 0FDA Expands Label of Cabotegravir and Rilpivirine Dual Injectable for Adults With HIV - 2 year(s) ago
The FDA label expansion means adults living with HIV can now receive an injection of cabotegravir and rilpivirine (Cabenuva) once every 2 months instead of once monthly.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
The @US_FDA label expansion means adults living with #HIV can now receive an injection of #cabotegravir and #rilpivirine (#Cabenuva) once every 2 months instead of once monthly. https://t.co/5VpIprTgBA
-
-
Mashup Score: 6FDA Approves Injectable Cabotegravir for PrEP - 2 year(s) ago
The therapy becomes the first injectable approved in the United States for this indication.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#ICYMI #Cabotegravir becomes the first injectable approved in the United States for #HIV prevention. #FDA @FenwayHealth #IDTwitter https://t.co/xSMGCEYY97
-
-
Mashup Score: 0
Long-acting cabotegravir plus rilpivirine worked with or without a lead-in for ART-naïve HIV patients.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
Long-acting #cabotegravir plus rilpivirine worked with or without a lead-in for ART-naïve #HIV patients. https://t.co/T0IurDoqa3
-
-
Mashup Score: 1Long-Acting Injectable PrEP for HIV Risk - 3 year(s) ago
An expert reviews cabotegravir, islatravir, lenacapavir, and what other promising agents that could redefine long-term HIV prevention.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
“I suspect this isn't going to be something that’s unique to long-acting #cabotegravir and is really going to push the field diagnostically as we look forward to monthly oral islatravir, the #islatravir implant, and subcutaneous #lenacapavir." #IDWeek https://t.co/zMOFl5dtym
-
-
Mashup Score: 0
Original Article from The New England Journal of Medicine — Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Source: New England Journal of MedicineCategories: Expert Picks, Latest HeadlinesTweet-
Long-acting injectable #cabotegravir (CAB-LA) given intramuscularly every 8 weeks was superior to daily oral #TDF-FTC in preventing #HIV infection among MSM and transgender women. Kudos for including #transgenderwomen in this study! https://t.co/wOa2eufR6M
-
-
Mashup Score: 16FDA Grants Priority Review for New Cabotegravir Long-Acting HIV Prevention and Treatment Drug - 3 year(s) ago
Cabotegravir has a target date of January 24, 2022 and would become the first long-acting HIV PrEP therapy approved.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
#BREAKING: @FDA_Drug_Info granted Priority Review for @ViiVHC's new #hivprevention drug, #cabotegravir long-acting. If approved, #cabotegravir would be the first long-lasting #HIV #PrEP therapy. https://t.co/yzgkOkmhIN
-
RT @mylittlebaklava: Want to sign up for cabotegravir injectable PrEP in Ukraine? Here’s our portal: https://t.co/9T2L2xYlvx #cabotegravir…